Cargando…

CSF proteomic signature predicts progression to Alzheimer's disease dementia

INTRODUCTION: Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (prodromal AD) are at increased risk to develop dementia. Still, underlying pathophysiological processes remain unclear. We studied whether cerebrospinal fluid (CSF) proteome changes are related t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vromen, Eleonora M., del Campo Milán, Marta, Scheltens, Philip, Teunissen, Charlotte E., Visser, Pieter Jelle, Tijms, Betty M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864445/
https://www.ncbi.nlm.nih.gov/pubmed/35229020
http://dx.doi.org/10.1002/trc2.12240
_version_ 1784655463383564288
author Vromen, Eleonora M.
del Campo Milán, Marta
Scheltens, Philip
Teunissen, Charlotte E.
Visser, Pieter Jelle
Tijms, Betty M.
author_facet Vromen, Eleonora M.
del Campo Milán, Marta
Scheltens, Philip
Teunissen, Charlotte E.
Visser, Pieter Jelle
Tijms, Betty M.
author_sort Vromen, Eleonora M.
collection PubMed
description INTRODUCTION: Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (prodromal AD) are at increased risk to develop dementia. Still, underlying pathophysiological processes remain unclear. We studied whether cerebrospinal fluid (CSF) proteome changes are related to time to clinical progression in prodromal AD. METHODS: We measured 671 CSF proteins in 49 prodromal AD individuals (67±7 years old, 22 [45%] female) from the Amsterdam Dementia Cohort. Associations of protein levels with time to dementia onset were tested with Cox regression models, followed by biological pathway enrichment analysis. RESULTS: Eighteen (36%) individuals developed dementia during follow‐up. In total, 128 (98%) proteins were associated with a 1.4‐ to 17‐fold increased risk of progression to dementia (all P < .05). These proteins showed enrichment for immune system processes, signal transduction, neuronal death, and neurodevelopmental biology. DISCUSSION: CSF proteome changes related to rate of progression to dementia can be detected in prodromal AD, providing more insight into processes involved in early AD pathophysiology.
format Online
Article
Text
id pubmed-8864445
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88644452022-02-27 CSF proteomic signature predicts progression to Alzheimer's disease dementia Vromen, Eleonora M. del Campo Milán, Marta Scheltens, Philip Teunissen, Charlotte E. Visser, Pieter Jelle Tijms, Betty M. Alzheimers Dement (N Y) Short Report INTRODUCTION: Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (prodromal AD) are at increased risk to develop dementia. Still, underlying pathophysiological processes remain unclear. We studied whether cerebrospinal fluid (CSF) proteome changes are related to time to clinical progression in prodromal AD. METHODS: We measured 671 CSF proteins in 49 prodromal AD individuals (67±7 years old, 22 [45%] female) from the Amsterdam Dementia Cohort. Associations of protein levels with time to dementia onset were tested with Cox regression models, followed by biological pathway enrichment analysis. RESULTS: Eighteen (36%) individuals developed dementia during follow‐up. In total, 128 (98%) proteins were associated with a 1.4‐ to 17‐fold increased risk of progression to dementia (all P < .05). These proteins showed enrichment for immune system processes, signal transduction, neuronal death, and neurodevelopmental biology. DISCUSSION: CSF proteome changes related to rate of progression to dementia can be detected in prodromal AD, providing more insight into processes involved in early AD pathophysiology. John Wiley and Sons Inc. 2022-02-23 /pmc/articles/PMC8864445/ /pubmed/35229020 http://dx.doi.org/10.1002/trc2.12240 Text en © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Report
Vromen, Eleonora M.
del Campo Milán, Marta
Scheltens, Philip
Teunissen, Charlotte E.
Visser, Pieter Jelle
Tijms, Betty M.
CSF proteomic signature predicts progression to Alzheimer's disease dementia
title CSF proteomic signature predicts progression to Alzheimer's disease dementia
title_full CSF proteomic signature predicts progression to Alzheimer's disease dementia
title_fullStr CSF proteomic signature predicts progression to Alzheimer's disease dementia
title_full_unstemmed CSF proteomic signature predicts progression to Alzheimer's disease dementia
title_short CSF proteomic signature predicts progression to Alzheimer's disease dementia
title_sort csf proteomic signature predicts progression to alzheimer's disease dementia
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864445/
https://www.ncbi.nlm.nih.gov/pubmed/35229020
http://dx.doi.org/10.1002/trc2.12240
work_keys_str_mv AT vromeneleonoram csfproteomicsignaturepredictsprogressiontoalzheimersdiseasedementia
AT delcampomilanmarta csfproteomicsignaturepredictsprogressiontoalzheimersdiseasedementia
AT scheltensphilip csfproteomicsignaturepredictsprogressiontoalzheimersdiseasedementia
AT teunissencharlottee csfproteomicsignaturepredictsprogressiontoalzheimersdiseasedementia
AT visserpieterjelle csfproteomicsignaturepredictsprogressiontoalzheimersdiseasedementia
AT tijmsbettym csfproteomicsignaturepredictsprogressiontoalzheimersdiseasedementia